

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addiese: COMMISSIONER FOR PATENTS PO Box 1450 Alexandra, Virginia 22313-1450 www.wepto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/656,503	09/05/2003	Rolf Dessauer	200310119-1	8341	
22879 HEWLETT PA	7590 10/09/200 ACKARD COMPANY	EXAM	EXAMINER		
P O BOX 272400, 3404 E. HARMONY ROAD INTELLECTUAL PROPERTY ADMINISTRATION FORT COLLINS, CO 80527-2400			ANGEBRANN	ANGEBRANNDT, MARTIN J	
			ART UNIT	PAPER NUMBER	
			1795		
			NOTIFICATION DATE	DELIVERY MODE	
			10/09/2008	ELECTRONIC	

## Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

JERRY.SHORMA@HP.COM mkraft@hp.com ipa.mail@hp.com

## Advisory Action Before the Filing of an Appeal Brief

Ī	Application No.	Applicant(s)		
	10/656,503	DESSAUER, ROLF		
	Examiner	Art Unit		
	Martin J. Angebranndt	1795		

	Martin 6. 7 ingebrannat	1750							
The MAILING DATE of this communication appe	ars on the cover sheet with the o	orrespondence add	ress						
THE REPLY FILED 21 July 2008 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.									
The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 3 °CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 3 °CFR 1.114. The reply must be filed within one of the following time periods:									
<ul> <li>a) The period for reply expiresmonths from the mailing</li> </ul>									
b)   The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire let	iter than SIX MONTHS from the mailing	date of the final rejection	n.						
Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TW MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).									
Extensions of time may be obtained under 37 CFR 1.138(a). The date on which the petition under 37 CFR 1.138(a) and the appropriate extension fee whave bean filled is the date for purposes of determining the period of extension and the corresponding amount for file 7. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filled, may reduce any earned patient term adjustment. See 37 CFR 1.704(b).  NOTICE OF APPEAL									
2. The Notice of Appeal was filed on A brief in comp	liance with 37 CFR 41.37 must be t	iled within two months	of the date of						
filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a).									
AMENDMENTS									
<ol> <li>The proposed amendment(s) filed after a final rejection, t</li> <li>They raise new issues that would require further cor</li> </ol>			cause						
(b) They raise the issue of new matter (see NOTE below		E below),							
<ul> <li>(c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or</li> </ul>									
(d) They present additional claims without canceling a c	corresponding number of finally reje	cted claims.							
NOTE: (See 37 CFR 1.116 and 41.33(a)).									
4. The amendments are not in compliance with 37 CFR 1.12	1. See attached Notice of Non-Co	mpliant Amendment (I	PTOL-324).						
5. Applicant's reply has overcome the following rejection(s):									
<ol> <li>Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).</li> </ol>									
7. For purposes of appeal, the proposed amendment(s): a) [		be entered and an e	planation of						
how the new or amended claims would be rejected is provided below or appended.  The status of the claim(s) is (or will be) as follows:									
Claim(s) allowed: none.									
Claim(s) objected to: none.									
Claim(s) rejected: <u>1-25.33,-36 and 38-41</u> .									
Claim(s) withdrawn from consideration: 26-32.									
AFFIDAVIT OR OTHER EVIDENCE	thefere are the data of Cross Ale		to a section of						
<ol> <li>The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).</li> </ol>									
<ol> <li>The affidavit or other evidence filed after the date of filing- entered because the affidavit or other evidence failed to o showing a good and sufficient reasons why it is necessary</li> </ol>	vercome <u>all</u> rejections under appea	l and/or appellant fail:	to provide a						
10. The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER									
The request for reconsideration has been considered but See Continuation Sheet.	does NOT place the application in	condition for allowan	ce because:						
12. Note the attached Information Disclosure Statement(s). (PTO/SB/08) Paper No(s) 13. Other:									
	/Martin J Angebranndt/ Primary Examiner, Art U	nit 1795							

Continuation of 11, does NOT place the application in condition for allowance because: The applicant's photolocyanine precursors are evidenced to be converted to a the phthalocyanine at a temperature of 200 degrees C (4/38-45 of US 2772284), while those of RD 39219 ad JP 58-008357 are taught to undergo the change at 100-150 degrees C. The claimed medium requires an NIR absorber (not the laser) and direction to this is provided in DR39219 to facilitate the use of laser/light rather than a thermal head to cause the color change. These references do not teach specific light to heat conversion materials or amounts thereof, and on on this basis it is reasonable for one skilled in the art to look to analogous art such as Kawauchi and Satake which describe NIR light to heat conversion materials and useful amounts thereof. As these materials have a demonstrated thermal sensitivity higher than that of the materials disclosed in the instant specification. there is a reasonable expectation that with an equivalent amount of IR absorber they would have a similar higher sensitivity in response to light. The applicant argues that the materials of 2772284 are much less sensitive than thoose of the instant application. This is a valid point, and example 6 of 2772284 teaches a the heating of the leuco due in the presence of ascorbic acid (a reducing agent) at 100 degrees for 15 minutes. Unfortunately this comparision is not a direct comparision as it occurs in solution. If the applicant has any data regarding the thermal sensitivity of the composition of example 1 of the instant application, the applicant could have a basis for arguing that the inventive composition has an increased sensitivity over those of the prior art. The applicant's representative mistakes the examiner's statements regarding the quality of the showing of the applicant in attempting to obviate the rejection for a 112 issue. They are different. The issue of hindsight reconstruction is undecut by the direction to the use of a laser form the coloration in RD 39219. (there is no rejection soley over RD 39219 and JP 58-008357). The thermal responsitivity taught by RD 39219 and JP 58-008357 address the sensitivity issues raised by the applicant. With respect to the arguments relating to Boggs et al., fail to account for the direction to binders in RD 39219 and the recitation of cellulosic and other binders including cellulose acetate abd its derivatives and polyvinyl butyral on page 8 of the translation of JP 58-008357 which overlap with those taught by Boggs et al.

/Martin J Angebranndt/ Primary Examiner, Art Unit 1795